p#s

In re Application for: Roberts et al.

Examiner: Amy M. Decloux

Serial No.: 09/843,342

Group Art Unit: 1644

RECEIVED

Filing Date: April 25, 2001

AUG 0 8 2002

For: IN VIVO LOADING OF MHC

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

Certificate of First-Class Mailing (37 C.F.R. § 1.8(a))

Thereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to Commissioner for Patents/ Washington, D.C. 20231

Dated: Myssell, 2007

Name of Person Certifying.

Printed Name: Talyn Antalek

## INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

## I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

ш	with the new patent application submitted herewith (57 C.F.R. § 1.97(a)).
	·
	Within three months after the filing date of the application or within three

With the new potent application submitted berewith (27 C.E.D. \$ 1.07(a))

months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.

Before the mailing date of a first Office Action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for any fees required pursuant to 37 C.F.R. § § 1.17(p) or 1.17(i)(1).

08/07/2002 HTECKLU1 00000067 071074 09843342

01 FC:126

180.00 CH

This Information Disclosure Statement is filed:

After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever comes first, and the Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for the fee (\$180.00) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.

This Information Disclosure Statement is filed:

After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.

The undersigned certifies that:

- ☐ Each item of information contained in the Information Disclosure

  Statement was first cited in any communication mailed from a foreign
  patent office in a counterpart foreign application not more than three
  months prior to the filing of this information disclosure statement.
- No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 more than three months prior to the filing of this Information Disclosure Statement.

## II. Copies of the Cited Items:

$\boxtimes$	Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
	Copies of only the following items listed on the attached Form PTO-1449 are enclosed:
	Copies of those items which are marked with an asterisk (*) in the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No and relied upon in this application for an earlier filing

date under 35 U.S.C. § 120. See 37 C.F.R. § 1.98(d).

Copies of those items which are marked with an asterisk (\*\*) in the attached Form PTO-1449 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.

## III. Concise Explanation of Relevance:

Citation of the above documents shall not be construed as:

- 1. an admission that the documents are necessarily prior art with respect to the instant invention;
- 2. a representation that a search has been made, other than as described above; or
- 3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. **07-1074** for any additional fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,

Elizabeth Lassen

Registration No. 31,845

Genzyme Corporation 15 Pleasant Street Connector P.O. Box 9322 Framingham, Massachusetts 01701-9322

Telephone: (508) 270-2553 Facsimile: (508) 872-5415